In 1885, the prophet and president of the Mormon Church, John Taylor, purchased about 100,000 acres of land in Mexico—in Chihuahua and Sonora, to be exact, some 200 miles south of the US border. More than 300 polygamous Mormon families from Utah migrated south to settle the land and to proselytize (even today you see the traveling twosomes of fresh-faced young men in their white shirts, ties and black name tags) and, many theorize, to preserve the practice of polygamy.
At the time, Mormon polygamists were being jailed and having their property seized. Utah itself was denied statehood by the federal government to halt the practice. Former presidential candidate Mitt Romney is descended from the Mexican settlements; his father, George, and grandfather, Marion, were born in Colonia Dublán, Mexico, in 1907.
But in 1910, many who had settled in northern Mexico began an exodus back to Utah due to anti-American sentiment fueled by the Mexican Revolution. Some say they returned with a local plant introduced by the natives: cannabis.
The Mormon Church, formally known as the Church of Jesus Christ of Latter-Day Saints (LDS), were and still are infamous for their teetotaler ways and as abstainers of vices of all kinds; hence, they didn’t look kindly on the brethren partaking of the plant, viewing it as a violation of Mormon scripture from the “Doctrine and Covenants,” section 89 (D&C 89), commonly referred to as the “Word of Wisdom.”
Great news! The Detroit Free Press, one of Michigan’s largest media outlets, has endorsed the Yes on 1 legalization campaign!
The paper’s supportive editorial echoed many of the Yes on 1 campaign’s core messages: marijuana prohibition wastes law enforcement resources, unfairly harms communities of color, and prevents the state from collecting millions in tax revenue that could fund critical social programs. This is a huge boost for Prop 1, but we have to make sure the momentum is carried forward into November.
You can help the Yes on 1 team by making a donation here. Supporters can also promote the effort by picking up Yes on 1 gear from the new campaign store. There, you’ll find some great items, including t-shirts, hoodies, and yard signs, with the official Yes on 1 logo.
We’re just a few weeks away from Election Day (November 6). Michigan residents should visit the Secretary of State’s voter page to get information about polling locations, absentee voting, and more. The deadline to register to vote is October 9. If you’re not already registered, click here for the registration form. Be sure to fill it out and deliver it to your city or town clerk’s office by October 9.
If you have friends or family in Michigan, please forward this email to them and ask them to vote “Yes” on Prop 1. I’m confident that if enough people pitch in, we’ll be celebrating another major victory on November 6.
Cannabidiol (CBD) may prevent haloperidol-induced orofacial dyskinesia, according to new research being published by the journal Brain, Behavior, and Immunity; the research was epublished by the National Institute of Health.
“The chronic use of drugs that reduce the dopaminergic neurotransmission can cause a hyperkinetic movement disorder called tardive dyskinesia (TD)”, states the study’s abstract. “The pathophysiology of this disorder is not entirely understood but could involve oxidative and neuroinflammatory mechanisms. Cannabidiol (CBD), the major non-psychotomimetic compound present in Cannabis sativa plant, could be a possible therapeutic alternative for TD.”
The study states that “This phytocannabinoid shows antioxidant, anti-inflammatory and antipsychotic properties and decreases the acute motor effects of classical antipsychotics. The present study investigated if CBD would attenuate orofacial dyskinesia, oxidative stress and inflammatory changes induced by chronic administration of haloperidol in mice.”
Furthermore, researchers “verified in vivo and in vitro (in primary microglial culture) whether these effects would be mediated by PPARγ receptors. The results showed that the male Swiss mice treated daily for 21 days with haloperidol develop orofacial dyskinesia. Daily CBD administration before each haloperidol injection prevented this effect.”
Mice treated with haloperidol “showed an increase in microglial activation and inflammatory mediators in the striatum. These changes were also reduced by CBD. ”
The study concludes by stating that; “In conclusion, our results suggest that CBD could prevent haloperidol-induced orofacial dyskinesia by activating PPARγ receptors and attenuating neuroinflammatory changes in the striatum.”
Judges in Seattle have agreed to clear past misdemeanor convictions for marijuana possession that were prosecuted before marijuana was legalized in Washington, reports the Seattle Times.
All seven judges of the Seattle Municipal Court have signed an order setting out a process for vacating the cases. The ruling follows City Attorney Pete Holmes’ filing of a motion in April asking the court to vacate the convictions.
In his motion, Holmes argued that possessing small amounts of marijuana is no longer illegal and clearing past convictions would right the injustices of a drug war that targeted people of color.
About 542 people could be affected. The ruling covers from about 1996 – when municipal courts, rather than county district courts, began handling those misdemeanors – to 2010 when Holmes became city attorney and stopped prosecuting low-level, non-violent marijuana cases.
“Insomuch as the conduct for which the defendant was convicted is no longer criminal, setting aside the conviction and dismissing the case serves the interests of justice,” wrote the judges in their ruling.
“For too many who call Seattle home, a misdemeanor marijuana conviction or charge has created barriers to opportunity — good jobs, housing, loans and education,” said Mayor Jenny Durkan in a public statement. “While we cannot reverse the harm that was done, we will continue to give Seattle residents a clean slate.”
Cannabinoids may provide a potential treatment option for prostate cancer, according to a new study published by the journal The Prostate.
“Cannabinoids have demonstrated anticarcinogenic properties in a variety of malignancies, including in prostate cancer”, states researchers. In the present study, they “explored the anti-cancer effects of the synthetic cannabinoid WIN 55,212-2 (WIN) in prostate cancer.”
For the study, “Established prostate cancer cells (PC3, DU145, LNCaP) were treated with varying concentrations of WIN”, and “Cell proliferation was determined by the MTS assay.” The anti-migration and anti-invasive potential of WIN “was examined by the wound healing assay and the matrigel invasion assay.” Cell cycle analysis was performed by flow cytometry, and mechanistic studies were performed by Western blot.
Animals were randomized into two groups: saline control and WIN (5 mg/kg), delivered by intraperitoneal injection three times per week for 3 weeks.
“WIN significantly reduced prostate cancer cell proliferation, migration, invasion, induced apoptosis, and arrested cells in Go/G1 phase in a dose-dependent manner”, claim researchers.
They conclude; “The following study provides evidence supporting the use of WIN as a novel therapeutic for prostate cancer.”
There’s no getting high off the good ole green without THC, but what is THC and how does it work?
Most smokers have heard this buzzword before, but not many know its chemical composition or the science behind how THC affects that brain and body. Every cerebral buzz you feel from smoking a well-packed bowl or leisurely spliff is directly proportional to the cannabis plant’s THC concentration. But why is that? In this article, the experts at Honest Marijuana tell you all the dirty details you’ll need to know to become an authority on all things THC (at least in your own head). Along the way, we’ll discuss such essential topics as:
What is THC?
How was THC discovered?
How does THC affect your brain?
How does THC affect your body?
How does potency affect the experience?
What are some common ways to consume THC?
How is THC medicinal?
That’s a lot to cover! So light up a toke and get ready to tuck in as we unearth the secrets of one of nature’s best beauties.
What Is THC?
Delta-9-tetrahydrocannabinol (THC) is a chemical secreted by the glands of the marijuana plant. It is found in high doses around the reproductive organs, as well as in the resin glands of the bud or flower of the female pot plant.
Although THC is only one of 85 plus chemical compounds known as cannabinoids found in the cannabis plant, THC is the primary psychoactive ingredient. It takes almost all the credit for creating your cerebral high.
Whereas humans use THC to get high, marijuana plants use THC to fend off natural predators like parasites, bacteria, and viruses. THC doesn’t produce antibacterial properties in people but, CBG (cannabigerol) a non-psychoactive compound also found in cannabis, does. Dr. Mary Jane always makes sure we get exactly what we need from our weed.…
Daily cannabis use is associated with greater odds of retention in treatment among those addicted to opioids, according to a new study published in the journal Addiction, and epublished online by the National Institute of Health.
“Cannabis use is common among people on opioid agonist treatment (OAT), causing concern for some care providers”, states the study. “However, there is limited and conflicting evidence on the impact of cannabis use on OAT outcomes. Given the “critical role of retention in OAT in reducing opioid-related morbidity and mortality”, researchers “aimed to estimate the association of at least daily cannabis use on the likelihood of retention in treatment among people initiating OAT.” As a secondary aim researchers “tested the impacts of less frequent cannabis use.”
The study comprised a total of 820 people who use illicit drugs (PWUD), who initiated OAT between December 1996 and May 2016. . Participants were followed for a median of 81 month.
The primary outcome was retention in OAT, defined as remaining in OAT (methadone or buprenorphine/naloxone-based) for two consecutive 6-month follow-up periods, and the primary explanatory variable was cannabis use (at least daily versus less than daily) during the same 6-month period. “Confounders assessed included: socio-demographic characteristics, substance use patterns and social-structural exposures.”
In adjusted analysis, “at least daily cannabis use was positively associated with retention in OAT [adjusted odds ratio (aOR) = 1.21, 95% confidence interval (CI) = 1.04-1.41]. Our secondary analysis showed that compared with non-cannabis users, at least daily users had increased odds of retention in OAT (aOR = 1.20, 95% CI = 1.02-1.43), but not less than daily users (aOR = 1.00, 95% CI = 0.87-1.14).”
Researchers conclude from this that “Among people who use illicit drugs initiating opioid agonist treatment in Vancouver, at least daily cannabis use was associated with approximately 21% greater odds of retention in treatment compared with less than daily consumption.”
According to a new study published by the Journal of Pain Research, THC/CBD can have “remarkable analgesic capabilities” in the treatment of chronic refractory pain caused by failed back surgery syndrome.
“This study aimed to evaluate pain and its symptoms in patients with failed back surgery syndrome (FBSS) refractory to other therapies, treated with a combination of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), in association with spinal cord stimulation (SCS)”, states the study’s abstract. “Outpatients referred at Pain Unit of San Vincenzo Hospital in Taormina (Italy), between September 2014 and January 2016”, were evaluated.
For the study, eleven FBSS patients diagnosed with neuropathic pain, and suffering from moderate to severe chronic refractory pain and undergoing treatment with SCS and a combination of THC/CBD for 12 consecutive months, completed the Douleur Neuropathique 4 questionnaire.
“All the included patients discontinued previous unsuccessful therapy at least 2 months before the beginning of the cannabinoid therapy, with the exception of the SCS that was continued. Patients received a fixed dosage of cannabinoid agonists (THC/CBD) that could be increased subjective to pain control response.” A Brief Pain Inventory questionnaire “was administered to measure pain and its interference with characteristic dimensions of feelings and functions”, and the “duration of treatment with SCS and THC/CBD combination was 12 months.”
Researchers found that “Effective pain management as compared to baseline result was achieved in all the cases studied. The positive effect of cannabinoid agonists on refractory pain was maintained during the entire duration of treatment with minimal dosage titration. Pain perception, evaluated through numeric rating scale, decreased from a baseline mean value of 8.18±1.07-4.72±0.9 by the end of the study duration (12 months) (P<0.001).”
The study concludes by stating that “The results indicate that cannabinoid agonists (THC/CBD) can have remarkable analgesic capabilities, as adjuvant of SCS, for the treatment of chronic refractory pain of FBSS patients.”
From left: Vivien Azer, Debra Borchardt, Emily Paxhia, Jessica Billingsly, Jeannette Ward Horton, Cynthia Salarizadeh and Tahira Rehmatullah
“This is the most interesting investment concept today,” TV personality Jim Cramer said about the high-flying cannabis industry as he kicked off the Green Market Summit at New York’s World Trade Center on Sept. 14.
Industry experts shared a vision of legal cannabis as a trillion dollar-plus disruptor of the pharmaceutical, food and beverage industries as more Fortune 500 companies take aim at the sector. Panel topics focused on the economics of cannabis, reaching out to consumers and the potential for marijuana to become more mainstream.
One major theme of the one-day conference that drew about 200 people centered around the growing role of Fortune 500 companies in the space, such as Constellation Brands and Molson Coors.
“Rob Sands is a very smart guy,” Cramer said about Constellation’s CEO, who inked a $4 billion deal with Canopy Growth over the summer to produce non-alcoholic cannabis beverages in Canada. It’s the largest investment yet by any major company in cannabis, but more are expected. Constellation owns Corona, Mondavi and many other alcohol brands.
Northern Mariana Islands Governor Ralph DLG. Torres has signed HB 20-178, the Taulamwaar Sensible CNMI Cannabis Act of 2018, into law.
“Today, our people made history”, said Governor Torres is a public statement. “We took a stand to legalize marijuana in the CNMI for recreational, medical, and commercial use”.
Torres’ signature on the measure comes shortly after it passed the Senate 6-0-2; it passed the House in August 108-1-1.
The new law allows those 21 and older to possess up to an ounce of marijuana, while also possessing up to 16 ounces of marijuana infused food products and 72 ounces of marijuana infused liquids. Licensed cannabis retail outlets are authorized to distribute the plant.
Under the new law there must be a Cannabis Commission appointed within 30 days. Once formed, the commission will have 180 days to create and adopt rules for the program.
Gover Torres’ signature of HB 20-178 makes the Northern Mariana Islands the first US territory to legalize cannabis.
The remote U.S. territory of the Northern Mariana Islands is so far ahead of the mainland U.S., it’s already late evening there. And the Northern Mariana Islands are also far ahead of the mainland U.S. when it comes to reforming marijuana laws.
The Northern Marianas just made history when it became the first jurisdiction in the U.S. where a governing body enacted legislation to both end marijuana prohibition and establish a system of regulation to replace it! Earlier today, Gov. DLG Torres signed the Taulamwaar Sensible CNMI Cannabis Act of 2018, after it was approved overwhelmingly by the commonwealth’s House and Senate.
All eight state laws that legalized, taxed, and regulated marijuana passed by voter initiative. And earlier this year, the Vermont Legislature enacted a bill that legalized adult-use possession and cultivation of marijuana. However, unlike the Northern Marianas’, Vermont’s law doesn’t include sales. (MPP spearheaded six of those nine campaigns.)
We’re proud of our allies at Sensible CNMI and lawmakers in the Northern Marianas for crafting a comprehensive, thoughtful bill that includes home cultivation, micro-producers, and on-site consumption. And we were honored to play a supporting role.
Meanwhile, the New Jersey Legislature could enact a law to legalize and regulate marijuana soon. Please consider making a generous donation to MPP so we can convince lawmakers in other states and territories to follow the Northern Marianas’ lead!
State Senator Floyd Prozanski is one of the Oregon’s legislative leaders and chair of the State Senate’s judiciary committee. He’s been heavily involved in crafting the state’s social-use legislation as well as its retail medical-marijuana program. He’ll be appearing at the International Cannabis Business Conference (ICBC) in Portland on Sept. 28. We conducted this interview with on Sept. 14.
How is Oregon dealing with its reported marijuana surpluses and what some describe as excessive cultivation licensing?
In 2017, my Senate Bill 1042, which passed out of the Senate Judiciary Committee that I chair, was going to give the governor what I call a tool in her toolbox to be able to enter into compacts with adjacent, adjoining states that had marijuana programs, either or both medical and recreational, and allow for the flow of cannabis products across state lines. I believe Oregon that the quality and the strains we produce in the medical arena would be in high demand for patients and individuals in the adjacent states. Unfortunately, the Senate leadership moved it to another committee for more consideration and it was not able to get out of that committee.
You’re talking about making Oregon-grown cannabis available in adjoining legal states like California and Washington?
Yes. Clearly, what we’d be doing at that point would be establishing a method to allow for these transfers to occur that would not be in violation of interstate commerce. To do that, we would to move the product from the Oregon into one of the three adjacent states that do have marijuana programs: California, Nevada and Washington. It would have to be through ground transportation only, because the federal government regulates air travel and marine travel.
“Allow cannabis to be available throughout the country. That would take away all of the diversion issues.”
This would allow us to address a lot of the concerns the Feds have regarding illegal diversion, because we would …
Less than seven weeks remain until the November 6 general election. The winners will have the power to determine New Hampshire’s marijuana policies for the next two years, so it is critically important for supporters of cannabis legalization to become informed and active participants in this year’s election.
As our voter guide explains, there are many strong contrasts between candidates’ positions on marijuana policy. In the race for governor, Gov. Chris Sununu (R) has not yet been convinced to support legalization, but Molly Kelly (D) and Jilletta Jarvis (L) have both taken clear positions in support.
The outcome of state Senate races will also be critical for our success, and those contests are often determined by a very small number of votes. If you are able to volunteer to help a good Senate candidate win in your area, please consider doing so. This could end up making a big difference in November!
While the new bill to legalize and regulate marijuana has not yet been revealed to the public, lawmakers and the Murphy administration are reportedly close to reaching a deal. However, it is not yet clear what the legislature intends to do to help people who are still suffering from the collateral consequences of a prior marijuana conviction.
New Jersey has been hotly debating the best way to legalize, tax, and regulate cannabis since Gov. Phil Murphy made that an important part of his campaign in 2017. MPP continues to advocate for adopting the best practices of other states to ensure that legalization allows opportunities for people impacted by marijuana prohibition and small businesses, and we’re encouraged that these ideas are reportedly being included in the legislation.
Learn more about the campaign and make a donation here.
Last month, a team of grassroots activists beat the odds and succeeded in qualifying a ballot initiative to legalize marijuana for adults in North Dakota. With just a few weeks left until Election Day, they need our help. Today, MPP is endorsing their effort and urging allies to support Measure 3.
There’s a real chance North Dakotans could approve Measure 3, which would end prohibition and create a process to seal criminal records for nonviolent marijuana convictions, but polling suggests the vote is going to be very close. Every dollar the campaign receives goes towards voter outreach and education. North Dakota has a small population, so your contribution could make all the difference.
A victory for Measure 3 would be huge. It would show that adult-use legalization can win anywhere, even in more rural and conservative states. It would also send a strong message to Congress that federal laws on marijuana are deeply unpopular throughout the country.
2018 is shaping up to be a big year for our movement. There are four marijuana-related state ballot questions in play, and each of them needs your help. Click the logos below to check out the campaigns. Please follow them on social media, spread the word to voters in those states, and donate what you can.
The Maryland Cannabis Policy Coalition just updated our voter guide for Maryland’s general election on Tuesday, November 6, 2018. All 188 of Maryland’s lawmakers are up for election this year, and we’ve graded the marijuana policy positions of those that responded to our candidate survey. We hope this guide is helpful as you prepare to vote!
Unfortunately, Republican candidate (and current governor) Larry Hogan’s views on the topic are not entirely clear. Please help us get his position firmly on the record! Consider attending a campaign event (listed on his Facebook page or Eventbrite) and respectfully asking him to explain his views. Or, you can send him an email. If you get a response, or just hear him comment on marijuana policy reform, please let us know.
And of course, don’t forget to register to vote! You must register by October 16, 2018 to vote in this election.
Both cannabidiolic acid (CBDA) and tetrahydrocannabinol (THC) show anti-inflammatory and anti-hyperalgesia effects on acute inflammation, according to a new study published by the journal Psychopharmacology, and epublished ahead of print by the National Institute of Health.
“The present study evaluates the anti-inflammatory and anti-hyperalgesia effects of CBD’s potent acidic precursor, cannabidiolic acid (CBDA), in a rodent model of carrageenan-induced acute inflammation in the rat hind paw, when administered systemically (intraperitoneal, i.p.) or orally before and/or after carrageenan”, begins the study’s abstract. “In addition, we assess the effects of oral administration of THC or CBDA, their mechanism of action, and the efficacy of combined ineffective doses of THC and CBDA in this model. Finally, we compare the efficacy of CBD and CBDA.”
Researchers found that “CBDA given i.p. 60 min prior to carrageenan (but not 60 min after carrageenan) produced dose-dependent anti-hyperalgesia and anti-inflammatory effects. In addition, THC or CBDA given by oral gavage 60 min prior to carrageenan produced anti-hyperalgesia effects, and THC reduced inflammation.”
The anti-hyperalgesia effects of THC “were blocked by SR141716 (a cannabinoid 1 receptor antagonist), while CBDA’s effects were blocked by AMG9810 (a transient receptor potential cation channel subfamily V member 1 antagonist). In comparison to CBDA, an equivalent low dose of CBD did not reduce hyperalgesia, suggesting that CBDA is more potent than CBD for this indication.”
Interestingly, “when ineffective doses of CBDA or THC alone were combined, this combination produced an anti-hyperalgesia effect and reduced inflammation.”
The study concludes by stating that “CBDA or THC alone, as well as very low doses of combined CBDA and THC, has anti-inflammatory and anti-hyperalgesia effects in this animal model of acute inflammation.”
The full study, conducted by researchers at the University of Guelph in Canada, can be found by clicking here.
While the US boasts the largest economy and stock market in the world, with giants Apple, Netflix and Google, Canada offers the largest cannabis companies for now.
To be sure, US cannabis companies such as MedMen Enterprises Inc. and Terra Tech Corp. have been expanding quickly. But Canada’s Tilray Inc., Canopy Growth Corp., Aurora Cannabis Inc., Aphria Inc., Cronos Group Inc. and others have bulked up significantly. The leading Canadian company, British Columbia-based Tilray, is currently valued at $14.4 billion.
With adult-use sales scheduled to begin in Canada on October 17, the spigot of capital has opened as investors pour money into the nation’s top pot stocks. The total cannabis market in Canada, including medical and recreational products, may yield up to $5.4 billion (C$7.2 billion) in sales next year, according to estimates from Deloitte.
With an eye on this growth, financiers and executives have been eager to offer investors new options. Tilray’s shares jumped 30% in their stock market debut on the NASDAQ on July 19, giving the company a total market value of $2.7 billion at the time. It’s a rich price tag for a business on track to earn just $80 million this year.
Market cap: $14.5 billion; owns Ontario-based LP, Tweed; with it’s recent $4 billion investment, Constellations Brands, whose stable of alcohol companies includes Corona and Mondavi, now owns 38% of Canopy.
Market cap: $7.3 billion; Alberta-based LP also owns Ontario-based LP, MedRelief Corp. as well as subsidiaries CannaMed and Hempco Food and Fiber; on Sept. 17, it was reported that Coca-Cola had contacted Aurora about launching a CBD soft drink in Canada.
A hemp legalization bill has been passed by a key Senate committee in New Jersey.
The Senate Economic Growth Committee passed Senate Bill 2491 today, sending it towards a vote by the full Senate. A companion bill to this measure, Assembly Bill 1330, was passed unanimously through the Assembly (67 to 0) in June.
According to its official text, SB 2491 “establishes an industrial hemp license for planting, growing, harvesting, possessing, processing, distributing, buying, or selling industrial hemp in the State.” The bill also “establishes procedures and requirements for persons applying to the Secretary of Agriculture for a license, including procedures and requirements for fingerprinting and criminal background checks for license applicants.”
The proposal defines industrial hemp as “an agricultural product that is part of the plant of any variety of Cannabis sativa L. with a delta-9-tetrahydrocannabinol concentration of 0.3% or less on a dry weight basis, and that is permitted pursuant to this act to be planted, grown, harvested, possessed, processed, distributed, bought, or sold by a person licensed pursuant to section 3 of this act.”
Louisiana state officials today nixed a regulation that prohibited physicians from recommending medical cannabis to more than 100 patients, while also easing renewal requirements for patients.
Earlier today the Louisiana Board of Medical Examiners, by a vote of 8 to 1, decided to remove an arbitrary rule that required physicians to stop recommending medical cannabis once they’ve recommended the medicine to 100 patients. The board also removed a requirement for patients to see their physician every 90 days in order to continue their ability to legally use medical cannabis (the vote on this was closer; 5 to 4).
Dr. Victor Chou, who was one of the first physicians in the state receive a license to recommend medical marijuana, told the board he met the patient cap just two weeks after opening his clinic, noting that he has “a waiting list of 700 patients”.
During their meeting the board was also asked to lift a rule that requires minors using the medicine to treat the symptoms of autism spectrum disorder to see a pediatric subspecialist in addition to their family physician. Proponents of the change urged the board to look into the issue at their next meeting which takes place in October.
Anxiety is a crippling mental disorder that affects more and more people every day. Even though this condition originates in the brain, it can have profound effects on the body as well. Anxiety can result in:
Numb or tingling hands.
Decreased blood flow.
And that’s just the tip of the anxiety-induced iceberg. Thankfully, treatments do exist for this crippling disease. But to add insult to serious injury, many of the treatments for anxiety produce side effects that are worse than the disorder itself.
Now, though, researchers are finding a treatment from an unlikely source: the marijuana plant. Certain chemicals in the marijuana plant can offer some seriously profound medical benefits when taken in the right way.
In this article, the experts at Honest Marijuana will introduce you to the chief chemical compound, known as CBD, that’s responsible for treating the many forms of anxiety. Along the way, we’ll answer such questions as:
What is CBD?
What is CBD oil?
Why use CBD oil for anxiety?
Is CBD oil addictive?
We’ll also investigate whether CBD oil gets you high and which CBD oil is right for treating anxiety. Let’s get started.
What Is CBD?
CBD is the abbreviation for the word cannabidiol (pronounced can-uh-BIH-dee-all), which is a member of a larger group of chemical compounds known as cannabinoids (pronounced CAN-uh-bih-noids).
Though you may have never heard of CBD or cannabinoids before, you’ve likely heard of CBD’s close relative THC. THC, or tetrahydrocannabinol, is the cannabinoid most responsible (and most famous) for getting you high. Other cannabinoids include:
All in all, 113 cannabinoids have been isolated from the three species of Cannabis plant (indica, sativa, and ruderalis). Though THC usually gets most of the press, CBD is quickly growing in popularity because of its myriad medical benefits.
Marijuana may help fight obesity, according to a new study published by the International Journal of Molecular Science.
Noting that “Obesity is an increasing health problem worldwide” and its “related comorbidities imply a high cost for the National Health System and diminish a patient’s life quality”, the study’s abstract states that”Cannabinoid receptors (CB) regulate thermogenesis, food intake and inflammation”.
In this study researchers found that “Stimulation of CB2 limits inflammation and promotes anti-obesity effects by reducing food intake and weight gain.” Stimulation of the CB2 receptors, of course, can occur through the consumption of cannabis and cannabinoids.”
The study’s full abstract can be found below:
Obesity is an increasing health problem worldwide. Its related comorbidities imply a high cost for the National Health System and diminish a patient’s life quality. Adipose tissue is composed of three types of cells. White adipocytes are involved in fat storage and secretion of hormones. Brown adipocytes are involved in thermogenesis and caloric expenditure. Beige adipocytes are transitional adipocytes that in response to various stimuli can turn from white to brown and could be protective against the obesity, enhancing energy expenditure. The conversion of white in beige adipose tissue is a potential new therapeutic target for obesity. Cannabinoid receptors (CB) regulate thermogenesis, food intake and inflammation. CB1 ablation or inhibition helps reducing body weight and food intake. Stimulation of CB2 limits inflammation and promotes anti-obesity effects by reducing food intake and weight gain. Its genetic ablation results in adiposity development. CB receptors are also responsible for transforming white adipose tissue towards beige or brown adipocytes, therefore their modulation can be considered potential anti-obesity target. CB1 principal localization in central nervous system represents an important limit. Stimulation of CB2, principally localized on peripheral cells instead, should facilitate the anti-obesity effects without exerting remarkable psychotropic activity.
If smoking marijuana is the king of all consumption methods, eating (i.e., ingesting) marijuana is the queen. Sure, dabbing (the prince in this metaphor) may usurp the throne one day, but for now, smoking and ingesting rule the roost. But before you head to the kitchen to dump your bag of weed into you favorite brownie mix, there are some important points to consider in your quest to learn how to make edibles.
But before you head to the kitchen and dump a bag of weed into your favorite brownie mix, there are some important points to consider. So that’s what we’re going to focus on in this article. Along the way, we’ll discuss:
What effects you can expect from eating cannabis
Why you should never dump raw bud into your food
The importance of decarboxylating your weed first
After that, we’ll show you how to make a cannabis infusion that you can use in any recipe and give you some tips on how to make edibles the honest way.
We’ll also let you in on a few super-secret methods (not really) for bringing you back down to earth should you get too high. Before we get to that, though, let’s start with what you can expect after eating marijuana edibles.
Effects Of Eating Cannabis
In terms of delivery, smoking and ingesting can be thought of, respectively, as the bullet train and the bike of the cannabis consumption world.
Smoking marijuana delivers the THC to your system lickety-split and takes you from normal to high in a matter of minutes or even seconds (like a bullet train). Ingesting marijuana, on the other hand, takes anywhere from 30 minutes to three or more hours to get you where you want to go (like a bike).
Additionally, when compared to smoking marijuana, ingesting your weed results in a much more intense high. To add to the appeal of ingesting, the effects …